Stock JNJ JOHNSON & JOHNSON
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Johnson & Johnson Swiss Exchange

Equities

JNJ

US4781601046

Delayed Swiss Exchange
Other stock markets
 11:36:39 2023-03-01 am EST 		5-day change 1st Jan Change
500 CHF +194.12% Intraday chart for Johnson & Johnson -.--% -.--%
02:34pm J&J: acquisition of Swiss eczema biotech company CF
02:10pm J&J to Acquire Skin Disease Treatment Rights from Numab in $1.25 Billion Deal DJ

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • With an enterprise value anticipated at 3.92 times the sales for the current fiscal year, the company turns out to be overvalued.
  • The company appears highly valued given the size of its balance sheet.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
JOHNSON & JOHNSON Stock Johnson & Johnson
-.--% 354B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.51% 727B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.78% 328B
B-
ABBVIE INC. Stock AbbVie Inc.
+1.35% 277B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.45% 243B
B+
NOVARTIS AG Stock Novartis AG
+7.59% 205B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-6.01% 203B
A+
AMGEN INC. Stock Amgen Inc.
+6.19% 164B
C+
PFIZER, INC. Stock Pfizer, Inc.
+0.31% 164B
C+
SANOFI Stock Sanofi
-0.97% 122B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. JNJ Stock
  4. JNJ Stock
  5. Ratings Johnson & Johnson